Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinqi Jiangtang Tablets for Multiple Metabolic Disorders in Elderly Patients with Type 2 Diabetes
ChiCTR2600124432Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), multiple metabolic disorders, hyperlipidemia and 2 more comparing Jinqi Jiangtang Tablets with Placebo (2 arms). Primary endpoints: Glycated hemoglobin compliance rate and Blood lipid compliance rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
Jinqi Jiangtang
03
Conditions
type 2 diabetes mellitus (T2DM)multiple metabolic disordershyperlipidemiahypertension (HTN)osteoporosis
Beyond the preview
Go deeper on ChiCTR2600124432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124432.